NCT06324981 Using AI Text Messaging to Improve AHA's Life's Essential 8 Health Behaviors
| NCT ID | NCT06324981 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Colorado, Denver |
| Condition | Cardiovascular Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,100 participants |
| Start Date | 2024-02-26 |
| Primary Completion | 2028-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 2,100 participants in total. It began in 2024-02-26 with a primary completion date of 2028-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of our pragmatic clinical trial is to compare how well three different strategies might do to reduce risk factors for cardiovascular disease in patients experiencing health disparities. The three different strategies are: 1) text messages, 2) interactive chatbot messages, and 3) chatbot messages with proactive pharmacist support. To measure cardiovascular risk factors, the investigators are using the American Heart Association's Life's Essential 8 (LE8) factors-blood glucose, cholesterol, blood pressure, physical activity, body mass index, diet, and smoking. This study focuses on improving cardiovascular risk factors for individuals facing health disparities, such as ethnic minorities, limited English proficiency, and low-income groups. These groups are more likely to be seriously affected by cardiovascular diseases. Self-management, or an individual's roles in managing their own chronic disease, includes lifestyle changes, medication adherence. Improving patients' self-management has been shown to improve health behaviors, better disease control and improved patient outcomes. The main question this study aims to answer is if one of the strategies (texting, chatbot, or chatbot with pharmacist support) may improve patient self-management and patient outcomes. The investigators will enroll up to 2,100 patients from three health systems that serve large populations experiencing health disparities: Denver Health, Salud Family Health Centers, and STRIDE Community Health Center. The results might help researchers and health care systems find the best ways to involve patients with health disparities to managing their chronic cardiovascular disease.
Eligibility Criteria
Inclusion Criteria: * diagnosis of one or more of the following CV risk factors (i.e., hypertension, diabetes or hyperlipidemia); and * the risk factor is at poor or intermediate health levels as defined by LE8 (e.g., BP\>140/90 mm Hg); and * the patient exhibits poor adherence to prescribed medication to treat the CV risk factor as defined by a delay in refilling the medication within the past 6 months. Exclusion Criteria: * patients who do not have cellphone; or * enrolled in hospice or palliative care; or * Non-English or Spanish speaking; or * enrolled in another clinical trial if denoted in the EHR.
Contact & Investigator
P. Michael Ho, MD PhD
PRINCIPAL INVESTIGATOR
University of Colorado, Denver
Frequently Asked Questions
Who can join the NCT06324981 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 89 Years, studying Cardiovascular Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06324981 currently recruiting?
Yes, NCT06324981 is actively recruiting participants. Contact the research team at lisa.sandy@cuanschutz.edu for enrollment information.
Where is the NCT06324981 trial being conducted?
This trial is being conducted at Denver, United States, Fort Lupton, United States, Wheat Ridge, United States.
Who is sponsoring the NCT06324981 clinical trial?
NCT06324981 is sponsored by University of Colorado, Denver. The principal investigator is P. Michael Ho, MD PhD at University of Colorado, Denver. The trial plans to enroll 2,100 participants.